Intravitreal bevacizumab (Avastin) for the treatment of bilateral acquired juxtafoveal retinal telangiectasis associated with choroidal neovascular membrane

Ruys, J; Laey, J. J. De; Vanderhaeghen, Y; Aken, Elisabeth Van

doi:10.1038/sj.eye.6702946

Cited by 18 publications

(13 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A single injection of intravitreal bevacizumab (1.25 mg) seems to be effective to improve VA and to decrease mean central foveal thickness. Several case reports of treatment with one or more intravitreal injections of bevacizumab (1.25 mg) [81,82,84] or ranibizumab (0.5 mg) [85,86] injections with a mean 6-month follow-up corroborated the improvement in VA, the resolution of subretinal and intraretinal fluid on OCT and the regression of SRNV with cessation of SRNV leakage in all cases. On the other hand, in a more recent retrospective series of 5 eyes with proliferative idiopathic juxtafoveolar retinal telangiectasis II treated with intravitreal bevacizumab with a longer follow-up (2 years), best-corrected VA was unchanged or improved after treatment [69].…”

Section: Retinal Telangiectasiasmentioning

confidence: 73%

See 1 more Smart Citation

Primitive Retinal Vascular Abnormalities: Tumors and Telangiectasias

et al. 2012

View full text Add to dashboard Cite

Primitive retinal vascular abnormalities are benign conditions of the retinal circulation that comprise vascular tumors and telangiectasias. The principal vascular tumors of the retina include retinal capillary hemangioma, cavernous hemangioma of the retina, racemose hemangiomatosis of the retina and retinal vasoproliferative tumor, while primary retinal telangiectasias include Coats’ disease, Leber’s miliary aneurysms and idiopathic juxtafoveal telangiectasias. In most cases, these alterations result in significant visual impairment due to exudation determined by the structural abnormalities of the retinal vasculature. The aim of this review is to assess the different clinical and diagnostic features of the single pathological entities and to discuss the available treatment modalities including the onset of intravitreal antivascular endothelial growth factor therapy.

show abstract

Section: Retinal Telangiectasiasmentioning

confidence: 73%

“…Several case series in the literature investigated the effects of bevacizumab or ranibizumab but with limited (12 months or less) follow-up [80,81,82,83,84,85,86,87]. A single injection of intravitreal bevacizumab (1.25 mg) seems to be effective to improve VA and to decrease mean central foveal thickness.…”

Section: Retinal Telangiectasiasmentioning

confidence: 99%

Primitive Retinal Vascular Abnormalities: Tumors and Telangiectasias

et al. 2012

View full text Add to dashboard Cite

show abstract

“…Results of photocoagulation and sub-retinal surgery for subretinal neovascular membrane (SRNVM) associated with IMT have not been good [2,3]. Photodynamic therapy (Novartis AG, Basel, Switzerland) and intravitreal bevacizumab (Genentech, Inc., South San Francisco, CA, USA) have been used, individually [4,5] and consecutively [6], for SRNVM secondary to IMT. To the best of our knowledge, no reports exist on the use of ranibizumab (Genentech, Inc.) as monotherapy or as a part of combination therapy in the treatment of proliferative type 2 IMT.…”

Section: Introductionmentioning

confidence: 98%

Combined photodynamic therapy and intravitreal ranibizumab as primary treatment for subretinal neovascular membrane (SRNVM) associated with type 2 idiopathic macular telangiectasia

Rishi

Shroff

Rishi

2008

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

“…The concept of a similar pathogenesis of neovascular AMD and MacTel type 2 was the rationale to study VEGF-inhibitors as a treatment option for neovascular MacTel type 2 ( Fig. 10; Charbel Issa et al, 2007b;Jorge et al, 2006;Karagiannis et al, 2009;Konstantinidis et al, 2009;Mandal et al, 2007;Mondal et al, 2010;Roller et al, 2011;Ruys et al, 2007;Shanmugam et al, 2007). Jorge and co-workers were the first to show a positive effect of bevacizumab in a patient with a juxtafoveolar neovascular membrane .…”

Section: Proliferative Stagementioning

confidence: 99%

Macular Telangiectasia Type 2

Heeren

Holz

Issa

2013

Microperimetry and Multimodal Retinal Imaging

View full text Add to dashboard Cite

Macular telangiectasia type 2 is a bilateral disease of unknown cause with characteristic alterations of the macular capillary network and neurosensory atrophy. Its prevalence may be underestimated and has recently been shown to be as high as 0.1% in persons 40 years and older. Biomicroscopy may show reduced retinal transparency, crystalline deposits, mildly ectatic capillaries, blunted venules, retinal pigment plaques, foveal atrophy, and neovascular complexes. Fluorescein angiography shows telangiectatic capillaries predominantly temporal to the foveola in the early phase and a diffuse hyperfluorescence in the late phase. High-resolution optical coherence tomography (OCT) may reveal disruption of the photoreceptor inner segment-outer segment border, hyporeflective cavities at the level of the inner or outer retina, and atrophy of the retina in later stages. Macular telangiectasia type 2 shows a unique depletion of the macular pigment in the central retina and recent therapeutic trials showed that such depleted areas cannot re-accumulate lutein and zeaxanthin after oral supplementation. There have been various therapeutic approaches with limited or no efficacy. Recent clinical trials with compounds that block vascular endothelial growth factor (VEGF) have established the role of VEGF in the pathophysiology of the disease, but have not shown significant efficacy, at least for the nonneovascular disease stages. Recent progress in structure-function correlation may help to develop surrogate outcome measures for future clinical trials.In this review article, we summarize the current knowledge on macular telangiectasia type 2, including the epidemiology, the genetics, the clinical findings, the staging and the differential diagnosis of the disease. Findings using retinal imaging are discussed, including fluorescein angiography, OCT, adaptive optics imaging, confocal scanning laser ophthalmoscopy, and fundus autofluorescence, as are the findings using visual function testing including visual acuity and fundus-controlled microperimetry. We provide an overview of the therapeutic approaches for both non-neovascular and neovascular disease stages and provide a perspective of future directions including animal models and potential therapeutic approaches.

show abstract

Intravitreal bevacizumab (Avastin) for the treatment of bilateral acquired juxtafoveal retinal telangiectasis associated with choroidal neovascular membrane

Cited by 18 publications

References 4 publications

Primitive Retinal Vascular Abnormalities: Tumors and Telangiectasias

Primitive Retinal Vascular Abnormalities: Tumors and Telangiectasias

Combined photodynamic therapy and intravitreal ranibizumab as primary treatment for subretinal neovascular membrane (SRNVM) associated with type 2 idiopathic macular telangiectasia

Macular Telangiectasia Type 2

Contact Info

Product

Resources

About